SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment. Issue 4 (21st March 2022)

• Record Type: Journal Article
• Authors: Egeli, Damla Buket; Hanfstein, Benjamin; Lauseker, Michael; Pfirrmann, Markus; Saussele, Susanne; Baerlocher, Gabriela M.; Müller, Martin C.
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 4(2022)
• Page Start: 955
• Page End: 962
• Publication Date: 2022-03-21
• Subjects: SOCS-2 -- chronic myeloid leukemia -- prognosis -- predictor; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.2010059
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: SOCS -2 gene expression at diagnosis has been suggested as a predictor of clinical outcome in chronic myeloid leukemia (CML). In this study SOCS-2 and GUS expression levels were determined by real-time PCR in pretherapeutic samples at diagnosis. First, three patient groups were compared after assessment at 48 months: optimal molecular responders ( n = 35), patients with resistance to imatinib ( n = 28), and blast crisis patients ( n = 27). A significant difference in SOCS-2 gene expression at diagnosis was observed comparing blast crisis vs. resistant patients ( p = 0.042) and optimal responders ( p = 0.010). Second, a validation sample of consecutively randomized patients ( n = 123) was investigated. No discriminative SOCS-2 gene expression cutoff could be derived to predict molecular or cytogenetic response, progression-free or overall survival. Although SOCS-2 gene was differentially expressed at the time of diagnosis in blast crisis patients when compared to other groups, a prognostic impact in consecutively randomized patients was not observed.